Ceres Nanosciences, Inc. (founded in 2008)
Ceres Nanosciences, Inc. commercializes the novel Nanotrap® technology, developed by a collaboration of scientists from the Center for Applied Proteomics and Molecular Medicine, and Italy’s ISS (Istituto Superiore di Sanitá). The Nanotrap® ESP particles are commercially available to researchers as a sample preparation kit targeting low molecular weight proteins and peptides. The Nanotrap® technology is also being applied to develop molecular diagnostic products, including a high sensitivity test for Lyme disease.
Theranostics Health (TH) (acquired by Avant Diagnostics, Inc. in 2016)
Theranostics Health (TH) was founded based upon the reverse phase array technology, novel tissue fixative reagents, and predictive and prognostic tissue biomarkers that can enable better selection and stratification of patients for treatment and enable the practice of personalized medicine. TH was acquired by Avant Diagnostics in 2016, who develop data-generating technology that helps make patient-focused precision medicine a reality in cancer treatment.
Virongy (founded in 2013)
Virongy serves the virology field by developing virological reagents and tools that support research and clinical investigation. Their mission is to provide scientists and clinicians with innovative technologies for studying viruses and viral vectors. Virongy’s services meet the highest academic and industry standards, and help facilitate scientific discoveries, clinical diagnostics, and disease treatment.